Screener
CG Oncology CGON Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 3,750 | 701 |
| Withholding taxes paid on net exercise of stock options | (194) | — |
| Stock issuance costs | (186) | (547) |
| Net cash provided by financing activities | 394,920 | 154 |
| Net decrease in cash and cash equivalents | (12,854) | (242,444) |
| Cash and cash equivalents at beginning of period | 32,490 | 257,068 |
| Cash and cash equivalents at end of period | $19,636 | $14,624 |
| Supplemental Disclosure of Cash Flow Information |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's financing cash flow?
- CG Oncology (CGON) reported financing cash flow of $1.92M in Q2 2026.
- What is the long-term trend for CG Oncology's financing cash flow?
- Over 2 years (2023 to 2025), CG Oncology's financing cash flow has grown at a 30.8% compound annual growth rate (CAGR), from $89.89M to $153.89M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about CG Oncology's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude